Implant Card and Patient Information Requirements in Tanzania

1. Key takeaways

Tanzania imposes a standalone obligation on implantable devices, set out in Part VIII §5.3 (Implant Card and Information to be Supplied to the Patient with an Implanted Device) of the June 2024 Compendium:

The manufacturer must supply the following information with the device:

• (a) the information needed to identify the device, including the device name, serial number, lot number, UDI and device model, together with the manufacturer name, address and website;
• (b) the warnings, precautions or measures to be taken by the patient or a healthcare professional regarding mutual interference with reasonably foreseeable external influences, medical examinations or environmental conditions;
• (c) the expected lifetime of the device and any necessary follow-up information;
• (d) other information required to ensure safe use by the patient;
• (e) relevant information available from the Essential Principles.

Language and access: the above information must be made available to the patient with the specific implant through any means that allows rapid access, and must be expressed in Kiswahili and English, written in a form easily understandable by a layperson, and updated as appropriate; updated information is provided to the patient through the website listed under item (a). In addition, the manufacturer must provide, for the information under item (a), an implant card delivered with the device.

Healthcare institution obligations: healthcare institutions must make the above information available to the patient implanted with the device in a way that allows rapid access, together with the implant card bearing the identity of the patient.

Exemption list (12 categories): sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors. The TMDA may add to or remove items from this list as necessary.

2. Legal basis

3. Expert insights

Insight 1: this is one of the rare mandatory bilingual requirements in Tanzania, and it targets the patient rather than the regulator.

Article 75 of GN 315 requires only English or Kiswahili (or both) for general labels; Part VIII §3.4(a) requires Kiswahili for devices for home use; while §5.3 requires patient information for implanted devices in Kiswahili and English side by side. The three provisions set different standards, and companies must not carry the impression that Kiswahili is optional into an implantable project. Translation and layperson readability are quality activities with their own lead time, and they should start when the card template is designed, not when the submission is assembled.

Insight 2: the UDI is written into the mandatory items of the implant card.

Item (a) expressly lists the UDI. This echoes change guideline G/003 §3.3, which treats adding a UDI as a notifiable change (no prior approval required; reported after completion): adding a UDI to an already marketed implanted device is a low-risk action, but the content of the implant card changes with it, so the change process should still be followed and the card version updated in step. Treating the card and the UDI record as one controlled document set avoids the drift between them.

Insight 3: the compliance vehicle can be a website, but the website address itself is part of the obligation.

§5.3 permits provision through any means allowing rapid access, and provides that updates are provided through that website — which means the website address in item (a) is not optional; it is part of the information architecture. If the address changes or the page goes offline, the patient information obligation develops a gap. Domain renewal, page continuity and archival of superseded versions belong in the device’s quality system, not in marketing’s discretion.

Insight 4: healthcare institutions carry an independent obligation, and the implant card must bear the identity of the patient.

The final paragraph of §5.3 requires healthcare institutions to provide the information together with the implant card bearing the identity of the patient. This is an obligation on the hospital side, but the card is supplied by the manufacturer with the device — in practice this means the manufacturer’s implant card must leave a field for entering the patient’s identity, otherwise the hospital cannot discharge its obligation. Card design and hospital workflow therefore have to be aligned, and feedback from implanting centres should be collected during design.

Insight 5: the exemption list can be amended, so it must not be treated as a permanent exemption.

The official text states that the TMDA may modify the list by adding or removing other types of implant as necessary. The exemption of sutures and plates is therefore a current state, not a fixed entitlement; it should be re-checked at every documentation update or before renewal. A product that has quietly moved out of the list would need the full card and bilingual information package in place before its next submission.

Insight 6: labelling non-compliance is a statutory refusal ground.

Article 15(1)(c) of GN 315 lists as a ground for refusing to issue or vary a registration that the device does not comply with the labelling requirements of the Regulations. The implant card and patient information fall under Part VIII requirements, so a labelling review failure feeds directly into the registration outcome. The card should therefore pass the same controlled-document review as the label itself.

4. Practical recommendations

1. Make the implant card a standalone controlled document, brought under change management (G/003) and version control.
2. Reserve a field for entering the patient’s identity, enabling healthcare institutions to discharge the final-paragraph obligation of §5.3.
3. Prepare Kiswahili and English bilingual text in parallel, in layperson-readable wording, consistent with the Essential Principles information.
4. Ensure the item (a) website remains available over the long term, and establish an information update process (including linkage to UDI and model changes).
5. Re-check the exemption list at every documentation update, confirming the product is still within its scope.
6. For large devices such as cardiac implants, samples may be substituted with label artwork plus 360° scaled photographs (Compendium Part I §4(d)), but the implant card obligations are not waived by the sample exemption.

5. Verification checklist

• □ It has been confirmed whether the product is an implanted device and whether it falls within the 12-category exemption list.
• □ The implant card includes the name, serial number, lot number, UDI and model plus the manufacturer name, address and website.
• □ Patient information is available in Kiswahili plus English bilingual text, layperson-readable.
• □ The card reserves a field for the patient identity.
• □ The item (a) website is live and covered by an update maintenance process.
• □ Whether UDI and card content changes trigger a change application has been assessed (G/003 §3.3, notifiable).

Regulatory information verified as of 29 October 2026. All provisions cited in this document have been checked against the official published text of the TMDA (June 2024 Compendium, Part VIII §5.3, §3.4(a), §5.1 and §6; GN. No. 315, Articles 74, 75 and 15(1)(c); change guidelines TMDA/DMD/MDA/G/003 §3.3); the review is repeated whenever the regulations are updated.

• Tanzania local resources: GRZAN can coordinate licensed local responsible persons (LRP) and distributor resources covering online submission, sample delivery, quality audit support and port clearance.
• Service capabilities: classification determination, registration and notification pathway selection, technical documentation (CSDT/STED) preparation and localization, GMDN and grouping strategy, clinical evidence organization, software and AI device submissions, change management, vigilance and PMS reporting, annual retention fee and renewal management.
• Contact: info@grzanglobal.com.